|
In the Media
April 30, 2007
Provectus readies next testing round
By News Sentinel staff
April 30, 2007
Knoxville-based Provectus Pharmaceuticals Inc. has completed dosing in the final patient enrolled in its
Phase I study of PV-10, a drug to be used with Stage III and IV metastatic melanoma (skin cancer).
It's also being tested for treatment of breast cancer and liver cancer.
Read the complete article here.
January 2, 2007
Drug Delivery Technology Article
In a Drug Delivery Technology article
titled "Utilizing Topical Delivery for Topical Diseases",
Provectus CEO Craig Dees, PhD discusses the advantages of topical application, as opposed to the current trend of systemic
routes of drug delivery, for the treatment of dermatological diseases.
Read the complete article here.
February 1, 2006
Drug Delivery Technology Special Feature Article
Drug Delivery Technology special feature article
titled "Revisiting Intralesional Delivery of Cancer Treatment",
Provectus CEO Craig Dees, PhD, compares Provectus’ novel cancer drugs to current cancer treatments.
Read the complete article here.
December 23, 2005
CNBC Europe interviews Provectus CEO Craig Dees, Ph.D.
Ross Westgate of CNBC Europe’s ”Adapting To Change” discusses Provectus’ unique
approach to focused cancer treatment in a live TV interview with Provectus CEO Craig Dees, Ph.D.
View the video interview here.
| 
